Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6224 | RPS20 | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 1.60e-30 | 1.53e+00 | -0.23 |
6224 | RPS20 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 7.15e-31 | 1.55e+00 | -0.23 |
6224 | RPS20 | 047563_1562-all-cells | Human | Prostate | BPH | 3.68e-84 | -8.20e-01 | 0.0791 |
6224 | RPS20 | 048752_1579-all-cells | Human | Prostate | BPH | 7.18e-180 | -1.12e+00 | 0.1008 |
6224 | RPS20 | 052095_1628-all-cells | Human | Prostate | BPH | 5.62e-119 | -9.43e-01 | 0.1032 |
6224 | RPS20 | 052097_1595-all-cells | Human | Prostate | BPH | 3.50e-137 | -1.01e+00 | 0.0972 |
6224 | RPS20 | 052099_1652-all-cells | Human | Prostate | BPH | 9.18e-124 | -1.01e+00 | 0.1038 |
6224 | RPS20 | Dong_P4 | Human | Prostate | Tumor | 1.92e-12 | -2.08e-01 | 0.0292 |
6224 | RPS20 | Dong_P5 | Human | Prostate | Tumor | 6.74e-90 | 3.01e-01 | 0.053 |
6224 | RPS20 | Dong_P6 | Human | Prostate | Tumor | 6.77e-39 | -5.80e-01 | 0.0371 |
6224 | RPS20 | P7 | Human | Prostate | Tumor | 1.62e-41 | 2.63e+00 | -0.1025 |
6224 | RPS20 | P9 | Human | Prostate | Tumor | 8.31e-21 | 1.36e+00 | -0.0285 |
6224 | RPS20 | P10 | Human | Prostate | Tumor | 2.88e-21 | 1.97e+00 | -0.0902 |
6224 | RPS20 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 4.05e-05 | -5.01e-01 | 0.1557 |
6224 | RPS20 | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 1.13e-10 | -5.18e-01 | 0.159 |
6224 | RPS20 | GSM5353217_PA_PB1A_Pool_2_S107_L004 | Human | Prostate | Tumor | 9.16e-05 | -6.07e-01 | 0.156 |
6224 | RPS20 | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 2.48e-15 | -7.08e-01 | 0.1479 |
6224 | RPS20 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 1.32e-18 | -8.37e-01 | 0.1531 |
6224 | RPS20 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 2.53e-42 | -4.98e-01 | 0.1633 |
6224 | RPS20 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 1.88e-44 | -6.07e-01 | 0.1608 |
Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/RPS20_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/RPS20_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RPS20_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RPS20_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/RPS20_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RPS20_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/RPS20_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RPS20_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/RPS20_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RPS20_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RPS20_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RPS20_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RPS20_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
GO:19033209 | Breast | Precancer | regulation of protein modification by small protein conjugation or removal | 38/1080 | 242/18723 | 1.71e-08 | 1.17e-06 | 38 |
GO:19033219 | Breast | Precancer | negative regulation of protein modification by small protein conjugation or removal | 21/1080 | 95/18723 | 8.09e-08 | 4.61e-06 | 21 |
GO:00313969 | Breast | Precancer | regulation of protein ubiquitination | 33/1080 | 210/18723 | 1.45e-07 | 7.82e-06 | 33 |
GO:00313979 | Breast | Precancer | negative regulation of protein ubiquitination | 19/1080 | 83/18723 | 1.85e-07 | 9.54e-06 | 19 |
GO:19017989 | Breast | Precancer | positive regulation of signal transduction by p53 class mediator | 10/1080 | 25/18723 | 5.77e-07 | 2.49e-05 | 10 |
GO:19017969 | Breast | Precancer | regulation of signal transduction by p53 class mediator | 19/1080 | 93/18723 | 1.20e-06 | 4.60e-05 | 19 |
GO:00723319 | Breast | Precancer | signal transduction by p53 class mediator | 26/1080 | 163/18723 | 2.23e-06 | 7.76e-05 | 26 |
GO:19046679 | Breast | Precancer | negative regulation of ubiquitin protein ligase activity | 6/1080 | 12/18723 | 2.48e-05 | 5.71e-04 | 6 |
GO:00514449 | Breast | Precancer | negative regulation of ubiquitin-protein transferase activity | 7/1080 | 19/18723 | 5.68e-05 | 1.17e-03 | 7 |
GO:19046668 | Breast | Precancer | regulation of ubiquitin protein ligase activity | 7/1080 | 23/18723 | 2.26e-04 | 3.42e-03 | 7 |
GO:00514386 | Breast | Precancer | regulation of ubiquitin-protein transferase activity | 10/1080 | 53/18723 | 7.88e-04 | 9.29e-03 | 10 |
GO:00513489 | Breast | Precancer | negative regulation of transferase activity | 27/1080 | 268/18723 | 3.49e-03 | 2.90e-02 | 27 |
GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
GO:190332014 | Breast | IDC | regulation of protein modification by small protein conjugation or removal | 43/1434 | 242/18723 | 1.71e-07 | 9.16e-06 | 43 |
GO:003139614 | Breast | IDC | regulation of protein ubiquitination | 37/1434 | 210/18723 | 1.50e-06 | 6.36e-05 | 37 |
GO:190332114 | Breast | IDC | negative regulation of protein modification by small protein conjugation or removal | 22/1434 | 95/18723 | 2.16e-06 | 8.69e-05 | 22 |
GO:007233114 | Breast | IDC | signal transduction by p53 class mediator | 30/1434 | 163/18723 | 5.82e-06 | 1.89e-04 | 30 |
GO:190179814 | Breast | IDC | positive regulation of signal transduction by p53 class mediator | 10/1434 | 25/18723 | 7.56e-06 | 2.27e-04 | 10 |
GO:003139714 | Breast | IDC | negative regulation of protein ubiquitination | 19/1434 | 83/18723 | 1.25e-05 | 3.29e-04 | 19 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPS20 | SNV | Missense_Mutation | | c.40N>A | p.Glu14Lys | p.E14K | P60866 | protein_coding | tolerated(0.08) | benign(0.101) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPS20 | SNV | Missense_Mutation | | c.235C>T | p.Arg79Cys | p.R79C | P60866 | protein_coding | deleterious(0.04) | benign(0.168) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
RPS20 | SNV | Missense_Mutation | | c.254N>G | p.His85Arg | p.H85R | P60866 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
RPS20 | SNV | Missense_Mutation | novel | c.325G>A | p.Gly109Arg | p.G109R | P60866 | protein_coding | deleterious(0.01) | probably_damaging(0.958) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPS20 | SNV | Missense_Mutation | rs371598524 | c.403N>A | p.Glu135Lys | p.E135K | P60866 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.905) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
RPS20 | SNV | Missense_Mutation | | c.340G>A | p.Glu114Lys | p.E114K | P60866 | protein_coding | tolerated(0.08) | benign(0.185) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
RPS20 | SNV | Missense_Mutation | | c.197G>T | p.Arg66Ile | p.R66I | P60866 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
RPS20 | SNV | Missense_Mutation | novel | c.304A>G | p.Thr102Ala | p.T102A | P60866 | protein_coding | deleterious(0.04) | possibly_damaging(0.852) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
RPS20 | SNV | Missense_Mutation | novel | c.190N>G | p.Thr64Ala | p.T64A | P60866 | protein_coding | deleterious(0.02) | possibly_damaging(0.896) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPS20 | SNV | Missense_Mutation | | c.232N>A | p.Asp78Asn | p.D78N | P60866 | protein_coding | deleterious(0.02) | probably_damaging(0.984) | TCGA-49-AARN-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |